-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Cognition Therapeutics, Raises Price Target to $6

Benzinga·12/19/2024 12:27:23
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and raises the price target from $5 to $6.